Market Overview

According to fortune business insights, the global in-vitro diagnostics (IVD) market size is witnessing steady growth, driven by the increasing prevalence of infectious and chronic diseases, rising demand for early disease detection, and continuous advancements in diagnostic technologies. According to Fortune Business Insights, the global in-vitro diagnostics market was valued at USD 77.73 billion in 2025 and is projected to grow from USD 81.83 billion in 2026 to USD 135.65 billion by 2034, registering a CAGR of 6.50% during the forecast period (2026–2034). North America dominated the global market with a 37.70% share in 2025.

In-vitro diagnostics refers to medical tests performed on biological samples, including blood, urine, saliva, and tissue, outside the human body. These tests help healthcare professionals detect, diagnose, monitor, and manage various medical conditions. They play a crucial role in identifying infectious diseases, cardiovascular disorders, cancer, autoimmune conditions, and other health complications. Increasing investments in research and development, growing awareness regarding preventive healthcare, and the adoption of personalized medicine are further supporting market expansion.

Major Players Profiled

Key companies operating in the global in-vitro diagnostics market include:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• QIAGEN N.V.

These companies are focusing on product innovation, strategic collaborations, acquisitions, and technological advancements to strengthen their market positions.

Market Segmentation

The market is segmented based on product type, technique, sample, setting, application, and end-user.

• By Product Type: Instruments and reagents & consumables. Reagents & consumables are expected to dominate with an 83.14% market share in 2026, supported by increasing testing volumes and demand for diagnostic kits.
• By Technique: Immunodiagnostics, clinical chemistry, molecular diagnostics, hematology, and others. Molecular diagnostics is projected to account for 30.54% of the market in 2026.